Oxygen Biotherapeutics (OXBT) Oxycyte Phase IIb Traumatic Brain Injury Trial Halted
Tweet Send to a Friend
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced that the Company, with unanimous approval from the Board of Directors, has elected ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE